(Total Views: 670)
Posted On: 08/13/2020 6:51:23 PM
Post# of 151014
Re: chazzledazzle #49360
Lots more tears and conspiracy theories on here than normal, I'll chalk that up to the 4.00 close, and let people grieve.
During a recent call, NP asked MM about uplisting by the third week of August. MM said and I quote "er uh yeah, it's possible" (I like MM this isn't poking fun at him). Uplisting by the 3rd week of August is likely another NP over promise. I def don't think uplisting in general is off the table. Still some time to prove me wrong about it being an over promise btw.
Like others I thought COVID was a waste of time and resources, in my opinion to date management has proven me wrong. I am at peace with the fact that other therapies maybe vaccines beats us to market. I think in the SC population we have a good chance of being better than most (maybe all) therapeutics. As for the mild to moderate population, there is less competition, and a large global market. Globally there will be a shortage of effective therapies at least for the first 12 months. We will have a safe and effective product to sell. I think the chance that we make 100-XXX million in the first 12 months somewhere in the world after approval is high.
All that being said I'm really here for Cancer, HIV, NASH, and maybe in 6 months I'll say MS and Alzheimers. COVID could provide us with some much needed cash in the short term, and am betting that it does.
During a recent call, NP asked MM about uplisting by the third week of August. MM said and I quote "er uh yeah, it's possible" (I like MM this isn't poking fun at him). Uplisting by the 3rd week of August is likely another NP over promise. I def don't think uplisting in general is off the table. Still some time to prove me wrong about it being an over promise btw.
Like others I thought COVID was a waste of time and resources, in my opinion to date management has proven me wrong. I am at peace with the fact that other therapies maybe vaccines beats us to market. I think in the SC population we have a good chance of being better than most (maybe all) therapeutics. As for the mild to moderate population, there is less competition, and a large global market. Globally there will be a shortage of effective therapies at least for the first 12 months. We will have a safe and effective product to sell. I think the chance that we make 100-XXX million in the first 12 months somewhere in the world after approval is high.
All that being said I'm really here for Cancer, HIV, NASH, and maybe in 6 months I'll say MS and Alzheimers. COVID could provide us with some much needed cash in the short term, and am betting that it does.
(3)
(0)Scroll down for more posts ▼
